# Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

> **NCT00769704** · PHASE3 · COMPLETED · sponsor: **BioVex Limited** · enrollment: 437 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Talimogene laherparepvec
- **BIOLOGICAL:** GM-CSF

## Key facts

- **NCT ID:** NCT00769704
- **Lead sponsor:** BioVex Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2013-02
- **Final completion:** 2014-09
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769704, "Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00769704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*